Outlook Therapeutics: Strengthened Case for ONS-5010 Drives Attractive Risk/Reward and Increased $10 Price Target
I'm PortAI, I can summarize articles.
Ascendiant analyst Edward Woo maintained a Buy rating on Outlook Therapeutics, setting a price target of $10. Woo's positive outlook is based on the potential of ONS-5010 (LYTENAVA) and its regulatory progress. Despite past FDA setbacks, the resubmitted BLA and new PDUFA date suggest imminent approval. Woo also notes successful commercial launches in the U.K. and Germany, and believes the company is well-funded. He sees significant growth potential in the wet AMD market and raises his 12-month price target to $10.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments